Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease


Health Canada has approved Ipsen SA's IPSEY Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans progressiva (FOP).

  • This decision marks the first approval for Sohonos worldwide.
  • Sohonos is an oral selective retinoic-acid receptor gamma (RARγ) agonist indicated to reduce the formation of heterotopic ossification (HO; new bone formation) to treat FOP. 
  • FOP is characterized by new bone formation outside of the normal skeletal system, like in soft connective tissues, in a process is known as heterotopic ossification, which can be preceded by painful soft tissue swelling or "flare-ups." 
  • Ipsen plans to file in the U.S. in H1 2022 and is in discussions with other regulatory authorities worldwide.
  • This approval is based on the ongoing MOVE Phase 3 trial data.
  • The trial is evaluating the efficacy and safety of a chronic/flare-up dosing regimen of palovarotene in decreasing new annualized HO volume in patients with FOP.
  • Price Action: IPSEY shares closed at $23.66 on Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!